Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

Boehringer Ingelheim Venture Fund

Profile, fund size and portfolio

Parent Boehringer IngelheimHQ Ingelheim am Rhein, GermanyFounded 2010

Boehringer Ingelheim Venture Fund is the corporate venture arm of Boehringer Ingelheim, a pharmaceutical and biotech company. It was founded in 2010 and is based in Ingelheim am Rhein, Germany. It invests from seed to Series A. Sectors it names: biotech and life sciences.

Evergreen allocationS2
EUR 350M
Companies backedS2
70+

Every figure links to its source

Snapshot

Investment stage: Seed to Series A
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeed to Series A
SectorsBiotech and life sciences
GeographyNorth America, Europe, Asia
OfficesIngelheim am Rhein, Germany, Cambridge, United States, Hong Kong, China, Boston, United States, Shanghai, China

Sources: S2 BIVF about us.

Graphic 1 of 3

Investment stage: Seed to Series A

Sources: S2 BIVF about us.

Download:Report a correction
Investments closed by company type
Data behind this graphic
Data behind this graphic
ItemCompaniesShare
Exits and IPOs1834.6%
Regenerative Medicine917.3%
Oncology (IO & targeted)611.5%
Anti-Infectives (AMR)59.6%
Digital Health47.7%
Not actively managed Portfolio47.7%
Auto-Immunity35.8%
Other Technologies and Indications35.8%

A company can carry more than one tag

Sources: S4 BIVF portfolio.

Graphic 2 of 3

Investments closed by company type

Sources: S4 BIVF portfolio.

Download:Report a correction
Scale and capital allocated
Data behind this graphic
Data behind this graphic
MeasureValueUnitKindSource
Headline sizeEUR 350MEvergreen allocationStated by the firm or its parentS2
Companies backed70+companiesStated by the firmS2
Companies on the firm's portfolio page52companiesCounted from the firm's own listS4

Sources: S2 BIVF about us; S4 BIVF portfolio.

Graphic 3 of 3

Scale and capital allocated

Firms and databases count companies, rounds and investments differently.

Sources: S2 BIVF about us; S4 BIVF portfolio.

Download:Report a correction

Where it invests and who leads it

Geography

Headquarters
Ingelheim am Rhein, Germany
Offices

Investment regionsS2

LeadersS3

Boehringer Ingelheim Venture Fund on LinkedIn

Key facts

FactValueStatusSource
Parent companyBoehringer Ingelheim (Privately held (no listing))Single sourceS1
Parent industryPharmaceuticals and biotechSingle sourceS1
Founded2010Single sourceS2
HeadquartersIngelheim am Rhein, GermanySingle sourceS5
StatusActiveSingle sourceS1
Capital sourceParent company onlySingle sourceS2
Headline sizeEUR 350M (Evergreen allocation)Single sourceS2
Companies backed70+Single sourceS2
People on the team page25Single sourceS3
StagesSeed, Series ASingle sourceS2

Portfolio

The firm's portfolio page lists 52 companies: 30 active, 18 exited.S4

The firm also states 70+ companies backed. The page list and the stated total measure different things.S2

Companies by status on the firm's list. Status as the firm tags itS4
TagCompaniesShare
Active3057.7%
Exited1834.6%
Portfolio by the firm's own tags. A company can carry more than one tagS4
TagCompaniesShare
Anti-Infectives (AMR)59.6%
Auto-Immunity35.8%
Digital Health47.7%
Oncology (IO & targeted)611.5%
Other Technologies and Indications35.8%
Regenerative Medicine917.3%
Not actively managed Portfolio47.7%
Exits and IPOs1834.6%

Shared portfolio with other corporate VCs

10 companies on the Boehringer Ingelheim Venture Fund portfolio page also appear on the portfolio page of at least one other firm in this directory. Matched by company website, or by name where no website is published.

FirmSharedCompanies in common
Comcast Ventures1Wellth
DaVita Venture Group1Wellth
JioGenNext1Wellth
LBBW VC1Acousia Therapeutics
3B Future Health Fund1AMAL Therapeutics
Mitsui & Co. Global Investment1ArmaGen Technologies
JJDC1Asgard Therapeutics
Roche Venture Fund1DiogenX
Pfizer Ventures1Imcheck Therapeutics
AstraZeneca-CICC Venture Capital1Rgenta
MP Healthcare Venture Management1Rigontec
UCB Ventures1RinRi Therapeutics

Companies backed by the most corporate VCs

Every company on the Boehringer Ingelheim Venture Fund list

52 companies, as listed on the firm's own website: 30 active, 18 exited, 4 listed.S4 Read the firm's list.

Active 30

  • Abalos Therapeutics
  • Acousia Therapeutics
  • Aignostics
  • ArrePath
  • Asgard Therapeutics
  • Aurobac Therapeutics
  • Bodyport
  • Brainomix
  • C-mo Medical Solutions
  • Centauri Therapeutics
  • DiogenX
  • EvlaBio
  • HepaRegenix
  • Libra Therapeutics
  • Nuevocor
  • Obulytix
  • ProTgen
  • QUANTRO Therapeutics
  • Refoxy Pharmaceuticals
  • Rewind Therapeutics
  • Rgenta
  • RiboX Therapeutics
  • RinRi Therapeutics
  • smartbax
  • STRM.BIO
  • SwitchKine
  • Synthetica Pioneering
  • Tacalyx
  • TECregen
  • Topas Therapeutics

Exited 18

  • Abexxa Biologics
  • AgomAb Therapeutics
  • Amal Therapeutics
  • ArmaGen Technologies
  • Dopavision
  • Home
  • Hookipa Pharma
  • ICD Therapeutics
  • Imcheck Therapeutics
  • NBE Therapeutics
  • Okairos
  • Our portfolio
  • Rigontec
  • STAT Dx
  • T3 Pharmaceuticals
  • Tilos Therapeutics
  • ViraTherapeutics
  • xCures

Listed 4

  • eTheRNA immunotherapies
  • Optina Diagnostics
  • T-knife
  • Wellth

For founders

ItemWhat the firm saysSource
StagesSeed, Series AS2
Leads roundsYesS6
Beyond capitalCompany formation expertise; board seat on portfolio companies; Team members each have more than 10 years in pharmaceutical R&D before investingS2
Contact formwww.boehringer-ingelheim-venture.com/contactS5

Recent rounds

DateCompanyRoundAmountSource
2026-09-08Cloverleaf BioSeedUSD 33MS8
2026-01-08TECregenSeedCHF 10MS6
2026-01-07STRM.BIOSeedUSD 8MS7

Fund vehicles

VehicleSizeYearSource
BIVF evergreen fundEUR 350M2010S2

Notable outcomes

IPOs and acquisitions of portfolio companies. Price shown only where published.

CompanyTypeAcquirer or exchangeSource
Hookipa PharmaIPOListed (portfolio page 'Exits and IPOs'; exchange not stated)S4

History

  1. Boehringer Ingelheim Venture Fund established.S2
  2. Detlev Mennerich is Global Head (joined BIVF 2014).S3
  3. Led TECregen CHF 10M seed (8 Jan).S6

About Boehringer Ingelheim

ItemDetailSource
Listed asPrivately held (no listing)S1
HeadquartersGermanyS5

Official pages

Read the firm's own pages for current information.

  • Website www.boehringer-ingelheim-venture.com
  • Portfolio www.boehringer-ingelheim-venture.com/portfolio

Sources

  1. S1BIVF homeFirm
  2. S2BIVF about usFirm
  3. S3BIVF teamFirm
  4. S4BIVF portfolioFirm
  5. S5BIVF contactFirm
  6. S6TECregen CHF 10 million seed financing led by BIVF (HTGF news)Portfolio company
  7. S7STRM.BIO $8 million Series Seed 2 (PR Newswire)Portfolio company
  8. S8Cloverleaf Bio $33M seed led by 4BIO Capital (GlobeNewswire)Portfolio company

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by Boehringer Ingelheim Venture Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.